The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
Abstract
Aim: Some of our obese patients who were receiving 10 mg/day sibutramine reported feeling hunger at night. To address this, we designed a randomized, prospective clinical trial to study the efficacy and safety of 10 mg sibutramine twice daily (bid), and compare this treatment with 120 mg orlistat three times daily (tid) and 850 mg metformin (bid). Methods: A total of 150 female patients with body mass index (b.m.i.) > 30 kg/m 2 were included. The subjects were all out‐patients at the Başkent University Endocrinology and Metabolism Clinic. Each individual was assigned randomly to receive 10 mg sibutramine bid (group 1; n = 50; mean age 42.27 ± 1.40 years), 120 mg orlistat tid (group 2; n = 50; mean age 42.13 ± 1.32 years) or 850 mg metformin bid (group 3; n = 50; mean age 43.58 ± 1.40 years). All patients took the medications for 6 months. Two patients from the sibutramine group and two from the orlistat group were withdrawn from the study because of side‐effects. Results: After 6 months of treatment, the sibutramine, orlistat, and metformin groups all showed significantly reduced b.m.i. (13.57%, 9.06% and 9.90% respectively); waist circumference (10.43%, 6.64%, and 8.10% respectively); fasting and postprandial blood glucose levels; insulin resistance as assessed by the homeostasis model for assessment of insulin resistance (HOMA)(38.63%, 32.73% and 39.28%, respectively); levels of total cholesterol, low‐density lipoprotein (LDLC) cholesterol, very low‐density lipoprotein (VLDLC) cholesterol, triglyceride, lipoprotein (a), and apolipoprotein B; uric acid level; pulse rate; and systolic and diastolic blood pressure. None of the groups showed any significant changes in levels of high‐density lipoprotein (HDLC) cholesterol, or apolipoprotein A1. There was a significantly greater fall in b.m.i. in the sibutramine group than in either of the other groups (p < 0.0001). Conclusions: The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females. Overall, treatment with 10 mg sibutramine bid is more effective than orlistat or metformin therapy in terms of weight reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Weight, Weight Change, and Coronary Heart Disease in Women: Risk Within the 'Normal' Weight Range
Willett, W. C. (1995) · JAMA · doi:10.1001/jama.1995.03520300035033 · Cited by 924
Miller, W., Koceja, D., & Hamilton, E. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800499 · Cited by 686
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Cited by
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations
Study, L. C., Köttgen, A., CARDIoGRAM Consortium, DIAGRAM Consortium, ICBP Consortium, MAGIC Consortium, Albrecht, E., Teumer, A., Vitart, V., Krumsiek, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2500 · Cited by 836
Meta-Analysis: Pharmacologic Treatment of Obesity
Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L. R., Hilton, L., Suttorp, M., Solomon, V., Shekelle, P. G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-7-200504050-00012 · Cited by 774
LeBlanc, E. S., O'Connor, E., Whitlock, E. P., Patnode, C. D., & Kapka, T. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00006 · Cited by 400
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258
Metadata
- Authors
- Gokcel, A., Gumurdulu, Y., Karakose, H., Melek Ertorer, E., Tanaci, N., Bascil Tutuncu, N., & Guvener, N.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2002-01
- Volume
- 4
- Issue
- 1
- Pages
- 49-55
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2164467222
- Cited by
- 164
- References
- 8
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. https://app.cochat.ai/papers/10.1046/j.1463-1326.2002.00181.x
- The paper
- Gokcel, A., Gumurdulu, Y., Karakose, H., Melek Ertorer, E., Tanaci, N., Bascil Tutuncu, N., & Guvener, N. (2002). Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, Obesity and Metabolism. https://doi.org/10.1046/j.1463-1326.2002.00181.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.